Toggle light / dark theme

(Natural News) A recent breakthrough in high-intensity focused ultrasound therapy (HIFU) technology has proven its use as an effective cancer treatment. A multi-institutional research team from China developed a semi-enclosed, spherical cavity transducer that can produce a focused, standing-wave field with a subwavelength-scale focal region and extremely high ultrasound intensity. The spherical cavity transducer appeared to generate tighter focal regions and greater pressure amplitude compared with the traditional concave spherical transducer. Researchers said the level of intensity generated by the new transducer design may lead to significant improvements in HIFU therapy. The findings were published in the Journal of Applied Physics.

HIFU is a non-invasive, targeted treatment that makes use of sound waves to eradicate cancer cells. HIFU uses an ultrasonic transducer to convert electrical signals into sound waves, then concentrates ultrasound into a small focal region to raise the temperature to more than 65 decrees Celsius, thereby killing cancer cells in the process without inducing damage to surrounding tissues. The technique works in the same manner as focusing sunlight through a lens, which helps eliminate the disease-causing cells.

HIFU can be used as an alternative to traditional cancer treatments such as chemotherapy and surgery.

Read more

Circa 2015


Researchers have used an infrared laser to cool water by about 2°C (36°F) — a major breakthrough in the field. As they are cooled by the laser, the nanocrystals developed by the University of Washington team emit a reddish-green ‘glow’ (shown) that can be seen by the naked eye.

‘Typically, when you go to the movies and see Star Wars laser blasters, they heat things up’, senior author and assistant professor of materials science and engineering at the University of Washington Peter Pauzauskie explained.

‘It was really an open question as to whether this could be done because normally water warms when illuminated.’

New York: Researchers say they have developed an innovative new system for delivering a malaria vaccine that shows promise in its effectiveness. By developing a vaccine that targets specific cells in the immune system, researchers from the University of Chicago in the US saw a much greater immune and antibody response to the vaccine.

Though a vaccine for malaria exists, it is only effective in 30 to 50 per cent of patients, and malaria is still responsible for nearly 500,000 deaths annually, according to the US Centers for Disease Control. “When compared to the current malaria vaccine option, our results are extremely exciting,” said Jeffrey Hubbell, a professor at the University of Chicago.

Read more

Fusion power — the process that keeps stars like the Sun burning — holds the promise of nearly unlimited clean power. But scientists have struggled for decades to make it a practical energy source.

Now, laser scientists say a machine learning breakthrough has smashed the standing record for a fusion power yield. It doesn’t mean fusion power is practical yet, but the prestigious journal Nature called the result “remarkable” and wrote that it has “major implications” — so, at the very least, it’s another hint that the long-deferred technology is starting to come into focus.

Read more

Now, this is awesome. A stationary robot, two mobile robots, and a human cooperating to perform a task. The humanoid robot also interprets human gestures and obeys those commands.

More information: http://www.co4robots.eu/


The Co4Robots MS2 scenario consists on collaborative grasping and manipulation of an object by two agents, the TIAGo mobile manipulator and a static manipulator; and a collaborating mobile platform and stationary manipulator to facilitate loading and unloading tasks onto the mobile platform.

TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or” WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market.

Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE: NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. Still, there is innovation and competitive potential brewing in the market at publicly-traded companies that are flying below the radar. One of those is Propanc Biopharma, Inc. (OTCQB: PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.

Propanc Biopharma, Inc. Company Overview

Read more